Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Zimmer Biomet Holdings Inc    ZBH

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Biomet 3Q Loss Widens On Charges; Sales Grow 5%

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/11/2012 | 04:51pm CET

("Biomet 3Q Loss Widens On Charges; Sales Grow 5%," at 7:03 a.m. EDT, misstated the hip sales increase in the sixth paragraph. The correct version follows:)

Biomet Inc.'s fiscal third-quarter loss widened on merger-related costs as strong sales for sports medicine, extremities and trauma helped drive the orthopedic medical-device maker's top-line growth.

Though privately held, Biomet's results are closely watched because the company reports earlier than larger competitors--such as Zimmer Holdings Inc. (>> Zimmer Holdings, Inc.), Stryker Corp. (SYK) and Johnson & Johnson (>> Johnson & Johnson)--and could foreshadow industry trends.

Biomet has seen its losses widen in recent quarters, weighed down by charges related to its $11.4 billion buyout in 2007 by a private-equity consortium including affiliates from The Blackstone Group, Goldman Sachs Capital Partners, Kohlberg Kravis Roberts & Co. and TPG. Sales have also been weak as patients, worried about out-of-pocket costs or long absences from work to recover, opt to defer hip and knee-replacement procedures. Biomet has said it is unclear when demand will come back.

For the quarter ended Feb. 29, Biomet reported a loss of $16.5 million, compared with a loss of $11.6 million a year earlier. Excluding merger and other special items, adjusted earnings fell to $55.1 million from $63.8 million. Sales jumped 4.5% to $708.9 million.

Gross margin slipped to 69% from 69.3%.

The company, which distributes products in about 90 countries, said worldwide hip sales increased 6%, while worldwide knee sales grew 4%. Sales for sports medicine, extremities and trauma were up 16%, while the spine and bone healing segment saw a 5% drop.

U.S. sales grew 5% while Europe sales rose 2.1%. International sales, which include Canada, South America, Mexico and the Asia-Pacific region, jumped 7.2%.

Last week, Biomet made a binding offer to acquire the global trauma business of Johnson & Johnson's DePuy Orthopaedics Inc. for about $280 million in cash, a deal the company said would greatly expand its sports, extremities and trauma business. Biomet also recently agreed to pay $23 million in penalties to settle U.S. allegations that it bribed doctors in Brazil, China and other countries over a period of years.

--By Anne Pallivathuckal and Melodie Warner, Dow Jones Newswires; 212-416-2283; [email protected]

Stocks mentioned in the article : Zimmer Holdings, Inc., Johnson & Johnson
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ZIMMER BIOMET HOLDINGS INC
11/23 ZIMMER BIOMET : to Present at 29th Annual Piper Jaffray Healthcare Conference
11/21 ZIMMER BIOMET : to Present at 29th Annual Piper Jaffray Healthcare Conference
11/08 ZIMMER BIOMET : to Present at Jefferies 2017 London Healthcare Conference
11/06 ZIMMER BIOMET : Management's Discussion and Analysis of Financial Condition and ..
11/03 ZIMMER BIOMET : Reports Third Quarter 2017 Financial Results
11/01 ZIMMER BIOMET : misses Street 3Q forecasts
11/01 ZIMMER BIOMET HOLDINGS, INC. : Results of Operations and Financial Condition (fo..
11/01 ZIMMER BIOMET : Reports Third Quarter 2017 Financial Results
10/27ZIMMER BIOMET HOLDINGS INC : quaterly earnings release
10/27 ZIMMER BIOMET HOLDINGS INC : Corporate News Blog - Zimmer Biomet Launches Vitali..
More news
News from SeekingAlpha
12/14 YOUR DAILY PHARMA SCOOP : Right Time To Buy Regeneron, Eli Lilly Gives Guidance,..
12/05 YOUR DAILY PHARMA SCOOP : Loxo Data, GW Pharmaceuticals' Q4 Results, Zynerba Pos..
11/23 Tracking Larry Robbins' Glenview Capital Management Portfolio - Q3 2017 Updat..
11/21 Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q3 2017 Update
11/14 Premarket analyst action - healthcare
Financials ($)
Sales 2017 7 776 M
EBIT 2017 2 436 M
Net income 2017 869 M
Debt 2017 9 436 M
Yield 2017 0,85%
P/E ratio 2017 25,33
P/E ratio 2018 20,02
EV / Sales 2017 4,15x
EV / Sales 2018 3,94x
Capitalization 22 843 M
Chart ZIMMER BIOMET HOLDINGS INC
Duration : Period :
Zimmer Biomet Holdings Inc Technical Analysis Chart | ZBH | US98956P1021 | 4-Traders
Technical analysis trends ZIMMER BIOMET HOLDINGS INC
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 131 $
Spread / Average Target 16%
EPS Revisions
Managers
NameTitle
Daniel P. Florin Director, Chief Executive & Financial Officer
Larry C. Glasscock Non-Executive Chairman
Adrian Furey Senior VP-Global Operations & Logistics
David J. Kunz VP-Global Quality, Clinical & Regulatory Affairs
Arthur Joseph Higgins Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ZIMMER BIOMET HOLDINGS INC10.00%22 843
MEDTRONIC PLC15.01%110 757
BAXTER INTERNATIONAL45.96%35 294
C R BARD INC47.78%24 208
HOYA CORPORATION13.27%19 153
ALIGN TECHNOLOGY145.12%18 746